{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:50:27Z","timestamp":1769151027137,"version":"3.49.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":498,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Lessons Learned<\/jats:title><jats:p>Treatment with the Aurora kinase A inhibitor yields often durable disease control, but limited tumor regression, in heavily pretreated patients with unresectable malignant pleural or peritoneal mesothelioma. In a limited sample size, MYC copy-number gain or gene amplification, a candidate predictive biomarker for alisertib, did not correlate with improved response numbers or patient outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Background<\/jats:title><jats:p>Malignant mesothelioma is an aggressive disease for which few effective therapies are available. The Aurora family kinases are critical for mitotic fidelity and highly expressed in mesothelioma, wherein their inhibition leads to growth arrest in vitro. We evaluated the efficacy of alisertib, an Aurora A kinase inhibitor, in relapsed malignant mesothelioma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twenty-six patients with previously treated, unresectable pleural or peritoneal mesothelioma were enrolled on a single-arm, single-institution phase II trial of alisertib at a dosage of 50 mg twice daily for 7 of every 21\u2009days. The primary endpoint was 4-month disease control rate. Secondary endpoints included overall response rate, progression free survival, overall survival, safety\/toxicity, and correlation of endpoints with MYC copy number.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 25 evaluable patients treated on study, 8 (32%) experienced 4-month disease control, surpassing the futility endpoint. There were no confirmed partial or complete responses. Median progression-free and overall survival were 2.8 months and 6.3 months, respectively. No associations between MYC copy number and outcomes were observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Alisertib has modest activity in this unselected malignant mesothelioma population. Several patients achieved durable disease control. Although the study did meet its prespecified futility endpoint, the sponsor elected to close the trial at the interim analysis.<\/jats:p><\/jats:sec>","DOI":"10.1634\/theoncologist.2020-0610","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T08:54:21Z","timestamp":1593593661000},"page":"e1457-e1463","source":"Crossref","is-referenced-by-count":13,"title":["A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma"],"prefix":"10.1093","volume":"25","author":[{"given":"Carl M.","family":"Gay","sequence":"first","affiliation":[{"name":"Department of Thoracic\/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Jack","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi Ming","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio I.","family":"Wistuba","sequence":"additional","affiliation":[{"name":"Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Ferrarotto","sequence":"additional","affiliation":[{"name":"Department of Thoracic\/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don L.","family":"Gibbons","sequence":"additional","affiliation":[{"name":"Department of Thoracic\/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonnie S.","family":"Glisson","sequence":"additional","affiliation":[{"name":"Department of Thoracic\/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merrill S.","family":"Kies","sequence":"additional","affiliation":[{"name":"Department of Thoracic\/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George R.","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of Thoracic\/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John V.","family":"Heymach","sequence":"additional","affiliation":[{"name":"Department of Thoracic\/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne S.","family":"Tsao","sequence":"additional","affiliation":[{"name":"Department of Thoracic\/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,7,19]]},"reference":[{"key":"2021122511045446000_R1","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1128\/MCB.02364-06","article-title":"MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy","volume":"27","author":"Hoar","year":"2007","journal-title":"Mol Cell Biol"},{"key":"2021122511045446000_R2","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1158\/0008-5472.CAN-05-3907","article-title":"Global gene expression profiling of pleural mesotheliomas: Overexpression of aurora kinases and P16\/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction","volume":"66","author":"Lopez-Rios","year":"2006","journal-title":"Cancer Res"},{"key":"2021122511045446000_R3","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nm.4107","article-title":"A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer","volume":"22","author":"Dauch","year":"2016","journal-title":"Nat Med"},{"key":"2021122511045446000_R4","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1097\/JTO.0000000000000202","article-title":"Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma","volume":"9","author":"Riquelme","year":"2014","journal-title":"J Thorac Oncol"},{"key":"2021122511045446000_R5","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"suppl 5","key":"2021122511045446000_R6","first-page":"v851","article-title":"A multicentre, randomized phase III trial comparing pembrolizumab (P) vs single-agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM) - Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"30","author":"Popat","year":"2019","journal-title":"Ann Oncol"},{"key":"2021122511045446000_R7","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jtho.2019.10.013","article-title":"Randomized phase II study of paclitaxel plus alisertib versus paclitaxel plus placebo as second-line therapy for SCLC: Primary and correlative biomarker analyses","volume":"15","author":"Owonikoko","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2021122511045446000_R8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/35048096","article-title":"Mitotic kinases as regulators of cell division and its checkpoints","volume":"2","author":"Nigg","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2021122511045446000_R9","doi-asserted-by":"crossref","first-page":"51786","DOI":"10.1074\/jbc.M306275200","article-title":"Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells","volume":"278","author":"Marumoto","year":"2003","journal-title":"J Biol Chem"},{"key":"2021122511045446000_R10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0092-8674(95)90374-7","article-title":"Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles","volume":"81","author":"Glover","year":"1995","journal-title":"Cell"},{"key":"2021122511045446000_R11","doi-asserted-by":"crossref","first-page":"46219","DOI":"10.1074\/jbc.M107540200","article-title":"Interaction and feedback regulation between STK15\/BTAK\/Aurora-A kinase and protein phosphatase 1 through mitotic cell division cycle","volume":"276","author":"Katayama","year":"2001","journal-title":"J Biol Chem"},{"key":"2021122511045446000_R12","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2353\/ajpath.2009.080721","article-title":"Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis","volume":"174","author":"Romagnoli","year":"2009","journal-title":"Am J Pathol"},{"key":"2021122511045446000_R13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.lungcan.2010.03.005","article-title":"Antiproliferative effect of Aurora kinase targeting in mesothelioma","volume":"70","author":"Crispi","year":"2010","journal-title":"Lung Cancer"},{"key":"2021122511045446000_R14","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.ijrobp.2006.12.018","article-title":"Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests","volume":"67","author":"Kim","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122511045446000_R15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"suppl 12","key":"2021122511045446000_R16","doi-asserted-by":"crossref","first-page":"B064a","DOI":"10.1158\/1535-7163.TARG-19-B064","article-title":"The Aurora kinase A-inhibitor alisertib is a potential candidate for combination with immunotherapy in small cell lung cancer","volume":"18","author":"Della Corte","year":"2019","journal-title":"Mol Cancer Ther"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1634%2Ftheoncologist.2020-0610","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2020-0610","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2020-0610","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/10\/e1457\/41920866\/oncolo_25_10_e1457.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/10\/e1457\/41920866\/oncolo_25_10_e1457.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T14:15:19Z","timestamp":1667225719000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/10\/e1457\/6443769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,19]]},"references-count":16,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,7,19]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2020-0610","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10,1]]},"published":{"date-parts":[[2020,7,19]]}}}